Congruence gets $32 million financing to advance genetic obesity candidate drug
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
With this designation, LG Chem will receive benefits such as exclusive sales rights in the US market for seven years, subsidies and tax cuts for clinical testing costs in the US, and preliminary consulting support related to development
Subscribe To Our Newsletter & Stay Updated